Drug intelligence / Profile preview

CR-1 (Curome Biosciences)

Development stage: Preclinical
Lead developer: Curome Biosciences

Overview

CR-1 is an early-stage therapeutic candidate being developed by CuromeBiosciences, a South Korean biotechnology company. It is currently positioned in the company's pipeline for the treatment of various inflammatory diseases. While CuromeBiosciences' core research platform focuses on the modulation of NQO1 (NAD(P)H:quinone oxidoreductase 1) for rare and degenerative conditions, specific pharmacological details for CR-1—including its molecular target, modality, and exact stage of development—have not yet been publicly disclosed. As of early 2024, the program is listed as 'coming soon' in official company documentation, indicating it is in the discovery or early preclinical phase.

Beyond the preview

Go deeper on CR-1 (Curome Biosciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR-1 (Curome Biosciences).

Explore the full profile